Monthly Cost Breakdown: Switching From Mounjaro To Wegovy
Understanding Monthly Costs When You Switch From Mounjaro To Wegovy
The decision to switch from Mounjaro to Wegovy often centres on understanding the long-term financial commitment. Wegovy's monthly costs follow a structured escalation pattern over 16 weeks before reaching maintenance pricing. This predictable pricing structure allows for better budgeting compared to other weight management options. The escalation period reflects the clinical requirement to gradually increase doses, minimising potential side effects whilst maximising therapeutic benefit.
Monthly costs begin at £79.99 for the 0.25mg starter dose (weeks 1-4), progressing to £94.99 for 0.5mg (weeks 5-8), then £99.99 for 1mg (weeks 9-12). The penultimate dose of 1.7mg costs £139.99 (weeks 13-16), before reaching the maintenance dose of 2.4mg at £209.99 from week 17 onwards. This transparent pricing structure eliminates surprises and enables informed financial planning for your weight management journey. Understanding these costs upfront helps patients commit to the full treatment protocol required for optimal results.
Wegovy Pricing Structure For Patients Switching From Mounjaro
EverydayMeds offers competitive pricing with discount codes applied at checkout to reach our final prices. New customers benefit from the FIRST40 discount code, whilst returning customers can use DOSE25 to maintain preferential pricing throughout their treatment. Our pricing reflects the premium quality of genuine Novo Nordisk Wegovy with full cold-chain handling from our GPhC-registered facility. Each pen is temperature-controlled throughout delivery to maintain pharmaceutical efficacy.
Bundle options provide convenience for patients who prefer fewer orders and Reliable Supply continuity. The Intro Duo combines 0.25mg and 0.5mg for £169.99, whilst the Progress Trio (0.5mg, 1mg, 1.7mg) costs £369.99 for three months of escalation. Our Ultimate Stability Trio provides three months of 2.4mg maintenance doses for £649.99. These bundles ensure treatment continuity without the concern of supply interruptions during critical escalation phases.
Clinical Evidence Supporting The Switch From Mounjaro To Wegovy
Clinical evidence from the STEP trial programme demonstrates Wegovy's efficacy in weight management. In the pivotal STEP 1 trial, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The STEP 2 trial showed sustained benefits in patients with type 2 diabetes, achieving 9.6% average weight loss. These results provide confidence for patients considering switching from alternative treatments.
The recent SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major cardiovascular events with Wegovy treatment. This additional benefit may influence the decision to switch from Mounjaro to Wegovy, particularly for patients with existing cardiovascular risk factors. However, individual responses vary, and switching decisions should always involve clinical consultation to ensure optimal outcomes based on personal medical history.
How Wegovy Works When Switching From Mounjaro Treatment
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural fullness hormone GLP-1. This mechanism differs from Mounjaro's dual GIP and GLP-1 approach, focusing specifically on GLP-1 pathways to reduce appetite and promote satiety. The medication works on brain appetite centres, potentially reducing food cravings and helping patients feel satisfied with smaller portions. Weekly injections maintain consistent medication levels, supporting sustained appetite regulation throughout each week. Understanding this mechanism helps patients appreciate why gradual dose escalation is essential for treatment success and tolerance. The prescription-only medicine must be used alongside lifestyle modifications for optimal effectiveness.
Ordering Process For Patients Switching From Mounjaro To Wegovy
EverydayMeds streamlines the switching process with our comprehensive 3-minute online clinical assessment. This assessment captures your previous Mounjaro experience and current health status to ensure Wegovy is appropriate for your circumstances. Our qualified prescribers review applications within 3 working days (or 24 hours with express service), considering your medical history and treatment goals. Once approved, your Wegovy prescription is dispensed from our GPhC-registered pharmacy #9012878 with next-day delivery. The entire process maintains clinical safety standards whilst providing convenient access to genuine pharmaceutical-grade medication.
Storage And Practical Considerations When Switching From Mounjaro To Wegovy
Wegovy offers practical advantages for patients switching from Mounjaro, particularly regarding storage flexibility. Whilst both require refrigeration at 2-8°C before first use, Wegovy can remain at room temperature (below 30°C) for up to 6 weeks once removed from the fridge, compared to Mounjaro's 21-day limit. The FlexTouch pen system provides intuitive injection delivery with clear dose indicators and safety features. Each pen delivers four weekly doses, and patients must follow the mandatory escalation schedule without skipping doses. This structured approach ensures optimal tolerance and effectiveness throughout the switching period. The prescription-only medicine requires proper disposal of used pens through pharmaceutical waste programmes.
Long-Term Cost Planning For Wegovy After Switching From Mounjaro
Annual cost planning becomes straightforward once patients reach the 2.4mg maintenance dose at £209.99 monthly. This equates to approximately £2,520 annually for ongoing treatment, representing a significant but predictable investment in weight management. The DOSE25 discount code for returning customers helps maintain competitive pricing throughout long-term treatment. Patients should factor in the initial 16-week escalation period when budgeting, as costs gradually increase before stabilising at maintenance level.
Weight management represents a long-term commitment, with clinical evidence showing weight regain when treatment stops. STEP trial extensions demonstrated patients regained approximately two-thirds of lost weight within one year of discontinuation. This evidence supports viewing Wegovy as an ongoing investment rather than a short-term solution. Planning for sustained treatment ensures better outcomes and prevents the disappointment of weight regain after achieving initial success.
Complete Your Switch From Mounjaro To Wegovy Today
EverydayMeds makes switching from Mounjaro to Wegovy straightforward with transparent pricing and clinical support. Our FIRST40 discount code reduces initial costs for new customers, whilst DOSE25 supports returning patients throughout their treatment journey. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment and secure next-day delivery of genuine Wegovy. Our qualified prescribers provide personalised treatment recommendations based on your individual circumstances and previous Mounjaro experience. Take control of your weight management journey with confidence, supported by clinical excellence and pharmaceutical expertise. Both Wegovy and Mounjaro are available from EverydayMeds — your prescriber can help determine which is right for you.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
